Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.30 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.30 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143975 | 0.91 | IDH1 (0.34) | IDH1PTGESF2F11SMO | |
| SCHEMBL31127100 | 0.91 | IDH1 (0.34) | IDH1PTGESF2F11SMO | |
| SCHEMBL19686925 | 0.90 | IDH1 (0.34) | IDH1PTGESF2F11SMO | |
| SCHEMBL19686411 | 0.87 | IDH1 (0.35) | IDH1PTGESF2F11SMO | |
| SCHEMBL21166293 | 0.82 | IDH1 (0.34) | IDH1F2F11METTL3NAPEPLD | |
| SCHEMBL21144021 | 0.82 | CCNA2 (0.36) | IDH1F2F11METTL3NAPEPLD | |
| SCHEMBL19686404 | 0.82 | IDH1 (0.34) | IDH1F2F11METTL3NAPEPLD | |
| SCHEMBL19686343 | 0.81 | IDH1 (0.35) | IDH1F2F11METTL3NAPEPLD | |
| SCHEMBL21143754 | 0.81 | IDH1 (0.36) | IDH1F2F11METTL3NAPEPLD | |
| SCHEMBL21143958 | 0.81 | IDH1 (0.35) | IDH1F2F11METTL3NAPEPLD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885PTGES 1318/4885TP53 4644/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885PTGES 1318/4885TP53 4644/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885PTGES 1318/4885TP53 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.